D. Taïeb and K. Pacak (Eds). Current Diagnostic and Therapeutic Approaches in Nuclear Endocrinology

Abstract

Nuclear Medicine, Molecular Imaging, and Theragnostics were all born thanks to the seminal contribution of Sodium Iodide, radiolabelled with I-131, being also relevant for our history other iodine radionuclides, such as I-123, I-124, and I-125. Nevertheless, although we started as Nuclear Thyroidologists, the editorial space for Endocrinology has become peripheral in the last decades, because of the greater development of other fields, such as oncology, neurosciences, cardiology, and so on. Among other things, the large family of somatostatin analogues, which also plays a very important role in the study of neuroendocrine tumors, has often found a place closer to oncology than to endocrinology. In this sense, a comprehensive and in-depth book on Nuclear Endocrinology, describing the state of the art of applications in diagnosis and therapy, is welcome. The Editors are David Taïeb, Professor of Nuclear Medicine at la Timone Hospital, associated with Aix-Marseille University, France, and Karel Pacak, Chief of the Section on Medical Neuroendocrinology at the National Institute of Child Health and Human Development, USA. They recruited in their editorial enterprise international experts in each specific field to reach a final result that is highly positive. In 895 pages, enriched by many figures and tables and with an updated bibliography, which also reports many old historical references, are widely, clearly, and effectively treated all the most important issues that have to be known today to utilize at best Molecular Imaging, Radionuclide Therapy, and Theragnostics in Endocrinology. The book is structured in 34 chapters, divided in 3 parts: (1) The Basics (Chapters 1–5); (2) Applications of Nuclear Medicine in the Evaluation of Endocrine Disorders (6–21); (3) Specific topics (22–34). To better understand the completeness and relevance of the contents, we report below the index: (1) Principles of Endocrinology; (2) Concepts in Metabolomics and Genomics of Endocrine Tumors; (3) Radioanatomy of Endocrine Glands; (4) PET Radiopharmaceuticals in Endocrine Tumors imaging; (5) Nuclear Imaging as a biomarker; (6) Thyroid Dysfunctions and Thyroid Nodules; (7) Medullary Thyroid Cancers; (8) Primary and Renal Hyperparathyroidism; (9) Adrenal Incidentalomas; (10) Imaging of ACTH-dependent Cushing’s Syndrome; (11) Primary Hyperaldosteronism; (12) Adrenocortical Carcinomas; (13) Head and Neck Paragangliomas; (14) Pheochromocytomas and Extradrenal Sympathetic Paragangliomas; (15) Neuroblastomas; (16) Pancreatic Neuroendocrine Tumors; (17) Gastrointestinal Neuroendocrine Tumors; (18) Unusual Neuroendocrine Tumors: Glucagonomas, VIPomas, somatostatinomas; (19) Pituitary Adenomas; (20) Adipose Tissue; (21) Diabetes and Beta Cell Tumors; (22) Prognostic Value of Nuclear Imaging in Endocrinology; (23) Precision Medicine for Neuroendocrine Tumors Management; (24) Nuclear Imaging in Endocrine Surgery; (25) Radioiodine Theranostics for Thyroid Cancer; (26) Diagnostic and Therapeutic Targeting of Norepinephrine Transporter; (27) Peptide Receptor Radionuclide Therapy; (28) Current and Future Approaches for Response Assessment in Endocrine Tumor-Directed Therapeutic Nuclear Medicine; (29) Internal Dosimetry in Targeted Molecular Radiotherapy: Principles and Clinical Applications; (30) Immuno-PET in Medullary Thyroid Carcinoma; (31) Radiation and Immunotherapy: Implications for Neuroendocrine Tumors; (32) Interventional Nuclear Medicine; (33) Nanotheranostics in Nuclear Medicine; (34) * Luigi Mansi [email protected]